ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

 

(b) Effective January 9, 2017, Mark J. Ahn, Ph.D. has voluntarily resigned from his position as Vice Chairman and director of Abeona Therapeutics Inc. (the "Company"). Dr. Ahn has served on the Company’s Board of Directors since September 2006. Dr. Ahn does not have any disputes or disagreements with the Company with regard to any of the Company’s policies, operations or practices.

 

 

 

 

 


About ABEONA THERAPEUTICS INC. (NASDAQ:ABEO)

Abeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Recent Trading Information

ABEONA THERAPEUTICS INC. (NASDAQ:ABEO) closed its last trading session down -0.05 at 6.05 with 594,227 shares trading hands.

An ad to help with our costs